Loading data for GLSI — first visit, this takes a few seconds.
Greenwich LifeSciences In... (GLSI)
NasdaqCM: GLSI
· Real-Time Price · USD
16.67
+1.36 (8.88%)
At close: Aug 24, 2026, 5:46 PM
The price, the headline numbers and the latest news, in one place.
Greenwich LifeSciences Inc. (GLSI) Stock Price, Analysis & Data
8.88% (1D)
No data available
| Bid | 12.48 |
| Market Cap | 245.13M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -22.47M |
| 1.45 | |
| -1.59 | |
| n/a | |
| -20.37 | |
| P/B (ttm) | 46.52 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2026 |
| Ask | 20.35 |
| Volume | 176,787 |
| Avg. Volume (20D) | 158,085 |
| Open | 16.16 |
| Previous Close | 15.31 |
| Day's Range | 15.54 - 17.34 |
| 52-Week Range | 7.78 - 34.10 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About GLSI
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to ev...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 25, 2020
Employees n/a
Stock Exchange NasdaqCM
Ticker Symbol GLSI
Financial Performance
In 2025, Greenwich LifeSciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -19.36M, an increase of 11.16%.
Financial StatementsEarnings Surprise
Greenwich LifeSciences has released their quarterly earnings on Aug 11, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.27 exceeds estimates by 0.06, with 10.00% YoY growth.
Greenwich LifeSciences Inc. is scheduled to release its earnings on Nov 12, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2